BR112021000018A2 - composições e métodos para tratamento de acidente vascular cerebral - Google Patents

composições e métodos para tratamento de acidente vascular cerebral

Info

Publication number
BR112021000018A2
BR112021000018A2 BR112021000018A BR112021000018A BR112021000018A2 BR 112021000018 A2 BR112021000018 A2 BR 112021000018A2 BR 112021000018 A BR112021000018 A BR 112021000018A BR 112021000018 A BR112021000018 A BR 112021000018A BR 112021000018 A2 BR112021000018 A2 BR 112021000018A2
Authority
BR
Brazil
Prior art keywords
fgf
compositions
methods
treating stroke
ischemic stroke
Prior art date
Application number
BR112021000018A
Other languages
English (en)
Inventor
W Jacobs John
R Meyerson Laurence
J Stegmann Thomas
Original Assignee
Venturis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Venturis Therapeutics Inc filed Critical Venturis Therapeutics Inc
Publication of BR112021000018A2 publication Critical patent/BR112021000018A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/30—Animals modified by surgical methods
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0375—Animal model for cardiovascular diseases

Abstract

a presente invenção inclui um método de tratamento de acidente vascular cerebral isquêmico, compreendendo a administração a um sujeito com acidente vascular cerebral isquêmico de fgf-1, fgf-1 1-155 , fgf-1 1-141 , ou combinações dos mesmos, em uma quantidade suficiente para atravessar o sangue barreira cerebral e reduzir ou eliminar o acidente vascular cerebral isquêmico. em um aspecto, o método também inclui a administração de pelo menos um outro agente terapêutico ao sujeito, antes, simultaneamente ou após o fgf-1, fgf-1 1-155 , fgf-1 1-141 ou combinações dos mesmos.
BR112021000018A 2018-07-03 2019-07-03 composições e métodos para tratamento de acidente vascular cerebral BR112021000018A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862693600P 2018-07-03 2018-07-03
PCT/US2019/040471 WO2020010180A1 (en) 2018-07-03 2019-07-03 Compositions and methods for treating stroke
US16/502,263 US20200009226A1 (en) 2018-07-03 2019-07-03 Compositions and Methods for Treating Stroke

Publications (1)

Publication Number Publication Date
BR112021000018A2 true BR112021000018A2 (pt) 2021-07-06

Family

ID=69060296

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021000018A BR112021000018A2 (pt) 2018-07-03 2019-07-03 composições e métodos para tratamento de acidente vascular cerebral

Country Status (6)

Country Link
US (1) US20200009226A1 (pt)
JP (1) JP2021529835A (pt)
BR (1) BR112021000018A2 (pt)
IL (1) IL279907A (pt)
MX (1) MX2021000157A (pt)
WO (1) WO2020010180A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021011878A1 (en) * 2019-07-18 2021-01-21 Venturis Therapeutics, Inc. Method of treating parkinson's disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733871A (en) * 1991-11-08 1998-03-31 The General Hospital Corporation Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration
US6214796B1 (en) * 1996-03-22 2001-04-10 The General Hospital Corporation Administration of polypeptide growth factors following central nervous system ischemia or trauma
AU4799700A (en) * 1999-04-27 2000-11-10 Board Of Regents, The University Of Texas System A composition and method for treatment of cerebral ischemia
WO2010042146A2 (en) * 2008-10-08 2010-04-15 Stephen William Smith Ultrasound brain scanning apparatus
US8461111B2 (en) * 2009-05-20 2013-06-11 Florida State University Research Foundation Fibroblast growth factor mutants having improved functional half-life and methods of their use
HUE037592T2 (hu) * 2009-08-26 2018-09-28 Bioelectron Tech Corp Eljárások cerebrális ischemia megelõzésére és kezelésére
CA2796459C (en) * 2010-04-16 2016-05-24 Salk Institute For Biological Studies Methods for treating metabolic disorders using fgf-1
WO2012006510A1 (en) * 2010-07-08 2012-01-12 Alkon Daniel L Fatty acid protein kinase c activators and anticoagulant for the treatment of stroke
EP2801377B1 (en) * 2011-03-04 2019-08-07 The Regents of The University of California Hydrogel comprising cells for local release of growth factors to mediate motor recovery after stroke
EP2719407A1 (en) * 2012-10-09 2014-04-16 EU Sol Biotech Co., Ltd. Kit for treating brain injury or stroke
AU2016205336A1 (en) * 2015-01-06 2017-08-03 Venturis Therapeutics, Inc. Angiogenic treatment of ischemic heart disease
WO2016130683A1 (en) * 2015-02-10 2016-08-18 University Of Washington Prolonged anti-diabetic effect of fibroblast growth factor 1 (fgf1)

Also Published As

Publication number Publication date
MX2021000157A (es) 2021-12-10
JP2021529835A (ja) 2021-11-04
IL279907A (en) 2021-03-01
WO2020010180A1 (en) 2020-01-09
US20200009226A1 (en) 2020-01-09

Similar Documents

Publication Publication Date Title
BR112018075998A2 (pt) composições antifúngicas sinérgicas e métodos das mesmas
BR112018008684A2 (pt) formulações de toxina botulínica injetáveis e processos de uso das mesmas com longa duração do efeito terapêutico ou cosmético
BR112015021371A2 (pt) uso de agonistas de receptor de formil peptídeo 2 para tratar doenças inflamatórias oculares
BR112018008805A8 (pt) proteínas de função dupla e composição farmacêutica que compreende a mesma
BR112018076114A2 (pt) composições tópicas de apremilast
BR112017012327A2 (pt) benzamidas substituídas por 1,3-tiazol-2-il.
BR112016006926A2 (pt) composições compreendendo um conjugado de ácido quínico com ácido cafeico, usos terapêuticos e cosméticos
BR112015021392A2 (pt) uso de agonistas do receptor de peptídeo formil 2 para tratar doenças dermatológicas
WO2007111992A3 (en) Methods and compositions for treating hypercholesterolemia and atherosclerosis
PE20211420A1 (es) COMPOSICIONES DE AGENTE DE ARNi DE PROTEINA PRECURSORA DE AMILOIDE (APP) Y METODO DE USO DE LAS MISMAS
BR112018005905A2 (pt) ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto?
BR112015017246A2 (pt) formulação farmacêutica que compreende um corticosteroide insolúvel e um corticosteroide solúvel
BR112016001544A2 (pt) composições farmacêuticas para injeção intraocular compreendendo agentes anti-bacteriano e anti-inflamatório, seu método de preparação, kit farmacêutico e uso dos referidos agentes no preparo das referidas composições farmacêuticas
PH12020550821A1 (en) Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration
BR112014030279A2 (pt) métodos para tratamento de neutropenia usando agonistas retinóide
BR112017006406A2 (pt) composições e métodos para o tratamento e profilaxia de infecções de sítio cirúrgico
BR112015000321A2 (pt) formulações de laquinimod sem agente alcalinizante
BR112017014361A2 (pt) métodos para aperfeiçoamento de terapia celular
BRPI0916885B8 (pt) composição farmacêutica
BR112018014467A2 (pt) tecnologia de sinergismo fármaco-anticorpo para o tratamento de doenças
ECSP21031200A (es) Uso de reboxetina para el tratamiento de narcolepsia
BR112021000018A2 (pt) composições e métodos para tratamento de acidente vascular cerebral
BR112017014914A2 (pt) terapia combinada para hipertensão pulmonar
BR112018013558A2 (pt) método de tratamento de uma doença hepática em um indivíduo, método de uso de um inibidor de caspase, método para diminuir ou sustentar uma classificação meld ou seus componentes, método para tratar, diminuir ou sustentar uma classificação meld ou seus componentes, método para tratar, diminuir ou sustentar uma classificação de child-pugh ou seus componentes, composição farmacêutica que compreende um inibidor de caspase, kit, método de tratamento, método de tratamento de cirrose hepática e prevenção de uma classificação meld elevada, método de tratamento de cirrose hepática e prevenção de uma classificação de child-pugh elevada
Opstrup et al. Systemic allergic dermatitis caused by diltiazem.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]